Rapport Therapeutics to Unveil Phase 2 Follow-Up Data for Seizure Drug at AAN 2026
Event summary
- Rapport Therapeutics will present Phase 2a trial results for RAP-219 in focal onset seizures at the 2026 AAN Annual Meeting on April 21.
- New 8-week follow-up data will be shared in a podium presentation.
- RAP-219 is a first-in-class TARPγ8-specific AMPA receptor negative allosteric modulator.
- The company aims to differentiate RAP-219 through targeted brain region specificity.
The big picture
Rapport Therapeutics is positioning RAP-219 as a potential first-in-class treatment with a differentiated mechanism targeting specific brain regions. The presentation at AAN 2026 comes at a time when precision medicine in neurology is gaining traction, with investors closely watching the clinical and commercial potential of targeted therapies. The company's approach aims to overcome limitations of traditional neurology drugs by minimizing adverse events associated with broader brain region effects.
What we're watching
- Clinical Efficacy
- How the 8-week follow-up data will impact the perceived clinical potential of RAP-219 in focal onset seizures.
- Pipeline Potential
- Whether the differentiated profile of RAP-219 can support its evaluation in additional indications like bipolar disorder and neuropathic pain.
- Regulatory Pathway
- The pace at which Rapport Therapeutics can advance RAP-219 toward Phase 3 trials based on these results.
Related topics